Clinical trials: Cancer-Associated Pain
Pain, Cancer
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time; explores what the body does to…
- Trial name
- NCT00805142
- Testing
- Tapentadol PR
- Where
- 21 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Janssen Pharmaceutical K.K.
Pain
Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study
The purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring satisfaction with pain treatment after administering fentanyl matrix in patients whose pain was not controlled sufficiently with the…
- Trial name
- NCT01816503
- Testing
- No intervention
- Volunteers
- 636 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pain, Cancer
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.
- Trial name
- NCT00126789
- Testing
- Fentanyl Transdermal Matrix Patch ZR-02-01
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- ZARS Pharma Inc.
Pain, Cancer Pain
Assessment of Updated Educational Materials for Instanyl®
The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use.
- Trial name
- NCT04938440
- Where
- United States
- Volunteers
- 536 people
- Sponsor
- Takeda
Opioid-Induced Constipation (OIC)
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain over a 6-month period.
- Trial name
- NCT01395524
- Testing
- NKTR-118
- Where
- 116 sites in United States, Australia and 2 more
- Volunteers
- 302 people
- Sponsor
- AstraZeneca
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01323790
- Testing
- NKTR-118
- Where
- 120 sites in United States, Belgium and 6 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Cancer, Bowel Dysfunction
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants…
- Trial name
- NCT00135577
- Testing
- alvimopan
- Where
- 40 sites in United States, Canada and 11 more
- Volunteers
- 67 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer
A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain
The purpose of this study is to evaluate the analgesic (painkiller) effectiveness and safety of combination of tramadol HCI (37.5 mg)/acetaminophen (325 mg) in the treatment of chronic cancer pain.
- Trial name
- NCT01968018
- Testing
- Tramadol HCI/acetaminophen
- Where
- Thailand
- Volunteers
- 35 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second…
- Trial name
- NCT01083615
- Testing
- custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Achieve Life Sciences
Liver Cancer, Pancreas Cancer
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers .
- Conditions
- Liver Cancer, Pancreas Cancer, Stomach Cancer, Bile Duct Cancer
- Trial name
- NCT04014478
- Testing
- Endovascular Denervation
- Volunteers
- 110 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Analgesics, Opioid, Pain
Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain
The primary purpose of this study was to characterize the pain control achieved with long-term repeated dosing of OROS hydromorphone (slow release) in patients with chronic cancer pain and the secondary purpose was to…
- Trial name
- NCT00410787
- Testing
- OROS hydromorphone HCI (slow release)
- Volunteers
- 68 people
- Sponsor
- Alza Corporation, DE, USA
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on…
- Trial name
- NCT01254630
- Testing
- V212
- Volunteers
- 5,305 people
- Sponsor
- Merck Sharp & Dohme LLC
Low Back Pain, Chronic Pain
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
The purpose of this 52-week open label study is to determine the long-term safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.
- Trial name
- SUMMIT-LTS (NCT02367820)
- Testing
- NKTR-181 BID tablets
- Where
- 56 sites in United States
- Volunteers
- 638 people
- Sponsor
- Nektar Therapeutics
Cancers, Pain
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00589823
- Testing
- Fentanyl citrate, Immediate release morphine sulphate
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Archimedes Development Ltd
Cancer Pain
Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients
The purpose of this study is to evaluate the effectiveness and tolerability of Once-Daily OROS ("Osmotic Release Oral System" [a controlled release oral medication delivery system in the form of a tablet]) hydromorphone for…
- Trial name
- NCT01621100
- Testing
- OROS hydromorphone
- Where
- 6 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Janssen Korea, Ltd., Korea
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901302
- Testing
- CB-5945
- Volunteers
- 61 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pain
Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient
This is a single center, open label, randomized, parallel group single dose intravenous (i.v.) administration study. The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.
- Trial name
- NCT01482936
- Testing
- Oxycodone (OxyNorm®) Injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Cancer, Pain
Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
This study is to evaluate the safety and tolerability of oxycodone control-released (CR) and/or immediate-released (IR) use in patients with moderate to severe cancer pain in a 3-months period in Taiwan.
- Trial name
- STOP Pain (NCT03176121)
- Testing
- Oxycodone
- Where
- 10 sites in Taiwan
- Volunteers
- 73 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Pain, Chronic
Ziconotide for Non-cancer Pain by Intrathecal Administration
Although ziconotide's marketing authorization does not restrict its use to a given type of pain, the drug has been used mainly in cancer patients.
- Trial name
- NCT06541184
- Testing
- Ziconotide [Prialt]
- Where
- 14 sites in France
- Volunteers
- 85 people
- Sponsor
- ESTEVE Pharmaceuticals SAS
Breakthrough Cancer Pain
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
The purpose of this observational study is: To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings…
- Trial name
- OASIS (NCT03895762)
- Testing
- Abstral Oral Disintegrating Tablet (ODT)
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd